Article
Understanding how long‐acting β2‐adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma – an update
20 Sept 2016
Abstract excerpt
In moderate‐to‐severe asthma, adding an inhaled long‐acting β2‐adenoceptor agonist (LABA) to an inhaled corticosteroid (ICS) provides better disease control than simply increasing the dose of ICS. Acting on the glucocorticoid receptor (GR, gene NR3C1), ICSs promote anti‐inflammatory/anti‐asthma gene expression.In vitro, LABAs synergistically enhance the maximal expression of many glucocorticoid‐induced genes....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.